[go: up one dir, main page]

KEGG   DRUG: Regdanvimab
Entry
D12241                      Drug                                   
Name
Regdanvimab (INN);
Regkirona (TN)
Sequence
(Heavy chain)
QITLKESGPT LVKPTQTLTL TCSFSGFSLS TSGVGVGWIR QPPGKALEWL ALIDWDDNKY
HTTSLKTRLT ISKDTSKNQV VLTMTNMDPV DTATYYCARI PGFLRYRNRY YYYGMDVWGQ
GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT
FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC
PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT
KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK
LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK
(Light chain)
ELVLTQPPSV SAAPGQKVTI SCSGSSSNIG NNYVSWYQQL PGTAPKLLIY DNNKRPSGIP
DRFSGSKSGT SATLGITGLQ TGDEADYYCG TWDSSLSAGV FGGGTELTVL GQPKAAPSVT
LFPPSSEELQ ANKATLVCLI SDFYPGAVTV AWKADGSPVK AGVETTKPSK QSNNKYAASS
YLSLTPEQWK SHRSYSCQVT HEGSTVEKTV APTECS
(Disulfide bridge: H22-H97, H155-H211, H231-L215, H237-H'237, H240-H'240, H272-H332, H378-H436, H'22-H'97, H'155-H'211, H'231-L'215, H'272-H'332, H'378-H'436, L22-L89, L138-L197, L'22-L'89, L'138-L'197)
  Type
Peptide
Class
Antiviral
 DG03174  Anti-SARS-CoV-2 agent
Remark
ATC code: J06BD06
Efficacy
Antiviral
  Type
Monoclonal antibody
Comment
Treatment of adults with coronavirus disease 2019 (COVID-19)
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko03262  Virion - Coronavirus
ko05171  Coronavirus disease - COVID-19
  Network
nt06171  SARS coronavirus 2 (SARS-CoV-2)
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J06 IMMUNE SERA AND IMMUNOGLOBULINS
   J06B IMMUNOGLOBULINS
    J06BD Antiviral monoclonal antibodies
     J06BD06 Regdanvimab
      D12241  Regdanvimab (INN)
Drug groups [BR:br08330]
 Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D12241  Regdanvimab
Antimicrobials [BR:br08307]
 Antivirals
  Entry, fusion or uncoating inhibitor
   Coronavirus spike protein
    D12241  Regdanvimab (INN)
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12241
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12241
Other DBs
CAS: 2444308-95-4
PubChem: 497620654
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system